| Literature DB >> 24707112 |
Riaz Ahmed Agha1, Christian F Camm2, Emre Doganay3, Eric Edison4, Muhammed R S Siddiqui5, Dennis P Orgill6.
Abstract
BACKGROUND: We recently conducted a systematic review of the methodological quality of randomised controlled trials (RCTs) in plastic surgery. In accordance with convention, we are here separately reporting a systematic review of the reporting quality of the same RCTs.Entities:
Keywords: Consort; Levels of evidence; Randomised controlled trials; Reporting quality; Research methodology
Year: 2013 PMID: 24707112 PMCID: PMC3971436 DOI: 10.1007/s00238-013-0893-5
Source DB: PubMed Journal: Eur J Plast Surg ISSN: 0930-343X
Fig. 1PRISMA flow diagram, illustrating how papers were selected (adapted from Moher et al. [17])
Summary statistics for CONSORT scores per year
| Year | Number of RCTs | Median CONSORT score | Range |
|---|---|---|---|
| 2009 | 26 | 9.9 | 4.5–17.3 |
| 2010 | 21 | 11.5 | 5.3–21.0 |
| 2011a | 10 | 12.9 | 9.0–15.0 |
aTo 30 June 2011 only
Fig. 2Compliance of the 57 RCTs with the individual items of the CONSORT statement
Compliance of RCTs with individual items of the CONSORT statement (ranked in order of increasing fulfilment)
| Criteria | Abbreviated description | Compliance (%) |
|---|---|---|
| New item (23) | Details of the experimental treatment and comparator as they were implemented | 7 |
| 10 | Who generated the allocation sequence, who enrolled participants and who assigned participants to their groups | 11 |
| 11 | Whether or not participants, those administering the interventions and those assessing the outcomes were blinded to group assignment | 26 |
| 16 | Number of participants (denominator) in each group included in each analysis and whether analysis was by ‘intention-to-treat’ | 27 |
| 1 | How participants were allocated to interventions—is it mentioned in the title | 31 |
| 7 | How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules | 31 |
| 13 | Flow of participants through each stage (a diagram is strongly recommended) | 38 |
| 18 | Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those prespecified and those exploratory | 38 |
| 8 | Method used to generate the random allocation sequence, including details of any restriction (e.g. blocking, stratification) | 40 |
| 9 | Method used to implement the random allocation sequence, clarifying whether the sequence was concealed until interventions were assigned | 40 |
| 21 | Generalizability (external validity) of the trial findings | 45 |
| 4 | Precise details of the interventions intended for each group and how and when they were actually administered | 52 |
| 14 | Dates defining the periods of recruitment and follow-up | 56 |
| 6 | Clearly defined primary and secondary outcome measures | 62 |
| 19 | All important adverse events or side effects in each intervention group | 64 |
| 15 | Baseline demographic and clinical characteristics of each group | 65 |
| 3 | Eligibility criteria for participants and the settings and locations where the data were collected | 69 |
| 5 | Specific objectives and hypotheses | 71 |
| 20 | Interpretation of the results, taking into account study hypotheses, sources of potential bias or imprecision | 75 |
| 12 | Statistical methods used to compare groups for primary outcome(s); methods for additional analyses, such as subgroup analyses and adjusted analyses | 76 |
| 17 | For each primary and secondary outcome, a summary of results for each group and the estimated effect size and its precision | 78 |
| 22 | General interpretation of the results in the context of current evidence | 89 |
| 2 | Scientific background and explanation of rationale | 98 |
Consort table adapted from Moher et al. [7]
Compliance of RCTs with additional criteria
| Additional criteria | Compliance (%) |
|---|---|
| AD1—eligibility criteria for care providers | 7 |
| AD2—details on the centres’ volume | 5 |
| AD3—number of care providers performing the treatment in each group | 38 |
| AD4—number of participants treated by each care provider | 31 |
| AD5—details on patients’ expectancies or preference for the treatments at baseline | 2 |
| AD6—baseline data of care providers | 0 |
| AD7—details on care providers’ compliance with the planned procedure | 4 |
| Ethical approval | 75 |
| Sources of funding | 47 |
| Trial registry number | 16 |
| Conflicts of interest | 61 |
Fig. 3CONSORT score against number of authors
Fig. 4CONSORT score against ISI 2010 impact factor
Fig. 5A bar chart of CONSORT score and number of RCTs against country